Potential Antiviral Options against SARS-CoV-2 Infection
Potential Antiviral Options against SARS-CoV-2 Infection
复制标题
DOI：
10.3390/v12060642
复制
发表时间：
2020-06-01
期刊：
影响因子：
4.7
通讯作者：
Kainov, Denis E.
中科院分区：
文献类型：
--
作者：
Ianevski, Aleksandr;Yao, Rouan;Kainov, Denis E.
截至2020年6月，严重急性呼吸道冠状病毒2型（SARS-CoV-2）感染人数持续飙升，全球病例已超过670万例。世界卫生组织（WHO）和联合国（UN）都强调需要更好地控制SARS-CoV-2感染。然而，开发针对SARS-CoV-2的新型病毒特异性疫苗、单克隆抗体和抗病毒药物既耗时又昂贵。恢复期血清和人体安全的广谱抗病毒药物（BSAA）是现成的治疗选择。本研究利用SARS-CoV-2株和Vero-E6细胞建立了中和试验。我们从康复患者中鉴定出最有效的血清用于治疗SARS-CoV-2感染的患者。我们还在Vero-E6细胞中筛选了136种针对SARS-CoV-2感染的人体安全广谱抗病毒药物，并鉴定了奈非那韦、盐霉素、阿莫地喹、奥巴克拉、恩替卡韦和高三尖杉酯碱。我们发现，口服病毒导向的奈非那韦和宿主导向的阿莫地喹的组合表现出最高的协同作用。最后，我们开发了一个网站，以传播有关COVID-19可用和新兴治疗方法的知识。
As of June 2020, the number of people infected with severe acute respiratory coronavirus 2 (SARS-CoV-2) continues to skyrocket, with more than 6.7 million cases worldwide. Both the World Health Organization (WHO) and United Nations (UN) has highlighted the need for better control of SARS-CoV-2 infections. However, developing novel virus-specific vaccines, monoclonal antibodies and antiviral drugs against SARS-CoV-2 can be time-consuming and costly. Convalescent sera and safe-in-man broad-spectrum antivirals (BSAAs) are readily available treatment options. Here, we developed a neutralization assay using SARS-CoV-2 strain and Vero-E6 cells. We identified the most potent sera from recovered patients for the treatment of SARS-CoV-2-infected patients. We also screened 136 safe-in-man broad-spectrum antivirals against the SARS-CoV-2 infection in Vero-E6 cells and identified nelfinavir, salinomycin, amodiaquine, obatoclax, emetine and homoharringtonine. We found that a combination of orally available virus-directed nelfinavir and host-directed amodiaquine exhibited the highest synergy. Finally, we developed a website to disseminate the knowledge on available and emerging treatments of COVID-19.